Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs CBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VNDA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

VNDA Overall Winner 6-Pillar Tally: VNDA 4 – 1 CBIO (1 Tie) Matrix Metrics: VNDA 7 – 3 CBIO

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Crescent Biopharma, Inc. (CBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas CBIO carries 37.4/100 (SELL) at $13.20 (N/M Forward P/E, -1432.6% operating margin).

  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile CBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs CBIO
VNDA NASDAQ Head-to-Head Winner
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.20
-6.71% 1D
Market Cap $533.8M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.42β · 63% Vol
Unified Composite Score
37.4 / 100 SELL
Tech 35.0 Fund 46.0 Flow 63.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.0%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $13.47 · SMA50: $14.65

6-Pillar Scorecard Institutional Category Breakdown (VNDA 4 – 1 CBIO)

Columns: Metric · VNDA · CBIO
1. Valuation Multiples VNDA
Forward P/E 103.1x N/M
Trailing P/E 103.1x N/M
PEG Ratio 2.23x N/M
EV / Revenue 0.9x 30.6x
2. Growth & Scale VNDA
Revenue Growth (YoY) +24.1% +0.0%
Earnings Growth (YoY) -95.9% +0.0%
TTM Revenue (USD) $229M $12M
Market Cap $238.9M $533.8M
3. Profitability & Quality VNDA
Gross Margin 93.6% 100.0%
Operating Margin -77.6% -1432.6%
Net Profit Margin -119.9% 0.0%
Return on Equity (ROE) -82.5% -160.8%
4. Balance Sheet & Cash Flow VNDA
Cash Generation (TTM) -$150M -$154M
Cash Flow Margin -65.4% N/A
Net Cash / Leverage $40M Net Cash $170M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CBIO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 163.3% (75th %ile) 127.8% (10th %ile)
Put/Call OI Skew N/A 1.07x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (7) vs CBIO (3)
Institutional Metric VNDA CBIO Criterion Row Edge
Market Capitalization
Scale
$238.9M $533.8M Larger Scale CBIO
Trailing P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Forward P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Revenue Growth (YoY)
Growth
+24.1% +0.0% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-77.6% -1432.6% Higher Margin VNDA
Net Profit Margin
Profitability
-119.9% 0.0% Higher Margin CBIO
Return on Equity (ROE)
Capital Efficiency
-82.5% -160.8% Higher ROE VNDA
52-Week Range Position
Momentum
4% ($4–$10) 24% ($9–$27) Stronger Trend CBIO
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 1.42β · 63% Vol Lower Realized Risk VNDA
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 37.4 / 100 (SELL) Higher Composite VNDA
Trailing 12M Revenue (USD)
Operating Scale
$229M $12M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev N/M PEG · 30.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) -$154M ($170M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CBIO +17.32 pp
VNDA: -5.83% · CBIO: +11.49%
3M Horizon CBIO +9.33 pp
VNDA: -30.24% · CBIO: -20.91%
6M Horizon CBIO +8.74 pp
VNDA: -37.58% · CBIO: -28.84%
1Y Horizon CBIO +14.25 pp
VNDA: -12.56% · CBIO: +1.69%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VNDA Revenue CBIO Revenue VNDA Op. Margin CBIO Op. Margin Margin Leader
FY2018 $190M N/A 11.3% N/A VNDA
FY2019 $230M N/A 10.0% N/A VNDA
FY2020 $250M $10M 11.0% -506.8% VNDA
FY2021 $270M $0M 15.7% -5470.7% VNDA
FY2022 $250M $0M 2.5% -63204.4% VNDA
FY2023 $190M $0M -7.2% -392752.9% VNDA
FY2024 $200M N/A -20.5% N/A VNDA
FY2025 $220M $10M -70.0% -1407.5% VNDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CBIO BREAKDOWN
144d in phase · OBV ACCUMULATION
Current IV 127.8%
IV Percentile 10th %ile
Put/Call OI Skew 1.07x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $533.8M market capitalization and -1432.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs CBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Crescent Biopharma, Inc. (CBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas CBIO carries 37.4/100 (SELL) at $13.20 (N/M Forward P/E, -1432.6% operating margin). Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile CBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VNDA leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with CBIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (100.0% gross margin, -1432.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VNDA cumulative revenue shifted +15.8% while CBIO shifted +0.0%. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CBIO.

VNDA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 30.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus CBIO (-160.8% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, CBIO carries 127.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 1.07x (Balanced) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.